Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
Nov 22 JAZZ ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
Nov 22 JAZZ Jazz Pharmaceuticals price target lowered to $163 from $166 at Piper Sandler
Nov 21 EXEL 3 Reasons Growth Investors Will Love Exelixis (EXEL)
Nov 21 JAZZ Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer
Nov 21 JAZZ Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
Nov 21 JAZZ Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Nov 20 OPK OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nov 20 EXEL Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity
Nov 20 HCWB HCW Biologics prices $6.9M registered direct offering at $1.03 per share
Nov 19 JAZZ Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
Nov 19 JAZZ Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
Nov 19 JAZZ Silver Ring Value Partners: Jazz Pharmaceuticals (JAZZ) Is a “High Uncertainty With Low Risk” Investment
Nov 19 HCWB HCW Biologics announces pricing of $6.9M registered direct offering, concurrent private placement
Nov 19 HCWB HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
Nov 18 HCWB Top Midday Gainers
Nov 18 HCWB Why Is Penny Stock HCW Biologics Surging On Monday?
Nov 18 JAZZ Jazz Pharmaceuticals: High Uncertainty, Low Risk
Nov 18 JAZZ Is Jazz Pharmaceuticals plc (JAZZ) the Best Immunotherapy Stock to Buy Now?
Nov 18 OPK NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo
Nov 18 HCWB HCW Biologics jumps on license agreement for immunotherapeutic product candidate
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags